Redcare Pharmacy publishes transcript of Q2 2026 earnings call

Reuters2026/07/30 10:23

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Redcare Pharmacy released a transcript of its Q2 2026 earnings call attended by analysts and investors, led by Olaf Heinrich and Hendrik Krampe.
Raised 2026 guidance: total revenue growth 15%-17%, Germany Rx revenue EUR 680 million-EUR 720 million, non-Rx growth 10%-12%, adjusted EBITDA margin 2.5%-3%.
Q2 revenue rose 20% year-over-year; adjusted EBITDA margin reached 3.5%, the highest level in 10 years; H1 EBIT turned positive at EUR 9 million.
Germany Rx revenue increased 58% year-over-year; Rx average basket value rose 14%; Germany Rx active customers reached 1,740,000; marketing spend targeted at about 5% of revenue.
Management flagged softer July trading with group growth slightly below 20% and single-digit non-Rx growth in Germany; signature-on-delivery for prescriptions seen costing under EUR 1 million annually.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redcare Pharmacy NV published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Redcare Pharmacy publishes transcript of Q2 2026 earnings call

You may also like

Crypto prices